CD274 and non-small cell lung carcinoma: mAbs that block the interaction between PD-L1 and PD-1 (e.g., durvalumab) improve PFS [16.8 versus 5.6 months (placebo)], the response rate, and its duration (72.8 versus 46.8% 18-month response) in stage III unresectable NSCLC pre-treated with platinum-based chemotherapy (23, 24).